Dianna Hussmann

Dianna Hussmann

Auto-generated profile, based on publicly available information

Dianna Hussmann

Department of Biomedicine, Aarhus University, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2016 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
TCThe BLUEPRINT consortium
The BLUEPRINT consortium
CBChristoph Bock
Christoph Bock
FHFlorian Halbritter
Florian Halbritter
FCFrancisco J Carmona
Francisco J Carmona
STSascha Tierling
Sascha Tierling
KZKun Zhang
Kun Zhang
DNA methylation patterns are altered in numerous diseases and often correlate with clinically relevant information such as disease subtypes, prognosis and drug response. With suitable assays and after validation in large cohorts, such associations can be exploited for clinical diagnostics and personalized treatment decisions. Here we describe the results of a community-wide benchmarking study comparing the performance of all widely used methods for DNA methylation analysis that are compatible with routine clinical use. We shipped 32 reference samples to 18 laboratories in seven different countries. Researchers in those laboratories collectively contributed 21 locus-specific assays for an average of 27 predefined genomic regions, as well as six global assays. We evaluated assay sensitivity on low-input samples and assessed the assays' ability to discriminate between cell types. Good agreement was observed across all tested methods, with amplicon bisulfite sequencing and bisulfite pyrosequencing showing the best all-round performance. Our technology comparison can inform the selection, optimization and use of DNA methylation assays in large-scale validation studies, biomarker development and clinical diagnostics.

3 June 2019 in Cancer Communications
Verified
Journal Article
Open access
PDF file
TLTrine Larsen
Trine Larsen
DHDianna Hussmann
Dianna Hussmann
ANAnders Lade Nielsen
Anders Lade Nielsen
Background: Programmed cell death ligand‐1 (PD‐L1) and ligand‐2 (PD‐L2) interaction with programmed cell death protein‐1 (PD‐1) represent an immune‐inhibiting checkpoint mediating immune evasion and is, accordingly, an important target for blockade‐based immunotherapy in cancer. In non‐small‐cell lung cancer (NSCLC), improved understanding of PD‐1 checkpoint blockade‐responsive biology and identification of biomarkers for prediction of a clinical response to immunotherapy is warranted. Thus, in the present study, we systematically described PD ‐ L1 and PD ‐ L2 expression correlated genes in NSCLC. Methods: We performed comparative retrospective analyses to identify PD ‐ L1 and PD ‐ L2 mRNA expression correlated genes in NSCLC. For this, we examined available datasets from the cancer cell line encyclopedia (CCLE) project lung non‐small‐cell (Lung_NSC) and the cancer genome atlas (TCGA) projects lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Results: Analysis of the CCLE dataset Lung_NSC identified expression correlation between PD ‐ L1 and PD ‐ L2 . Moreover, we identified expression correlation between 489 genes and PD ‐ L1 , 191 genes and PD ‐ L2 , and 111 genes for both. PD ‐ L1 and PD ‐ L2 also expression correlated in TCGA datasets LUAD and LUSC. In LUAD, we identified expression correlation between 257 genes and PD ‐ L1 , 914 genes and PD ‐ L2 , and 211 genes for both. In LUSC, we identified expression correlation between 26 genes and PD ‐ L1 , 326 genes and PD ‐ L2 , and 13 genes for both. Only a few genes expression correlated with PD ‐ L1 and PD ‐ L2 across the CCLE and TCGA datasets. Expression of Interferon signaling‐involved genes converged in particular with the expression correlated genes for PD ‐ L1 in Lung_NSC, for PD ‐ L2 in LUSC, and for both PD ‐ L1 and PD ‐ L2 in LUAD. In LUSC, PD ‐ L1 , and to a lesser extent PD ‐ L2, expression correlated with chromosome 9p24 localized genes, indicating a chromosome 9p24 topologically associated domain as an important driver of in particular LUSC PD ‐ L1 expression. Expression correlation analyses of the PD‐L1 and PD‐L2 receptors programmed cell death protein‐1 (PD‐1), Cluster of differentiation 80 (CD80), and Repulsive guidance molecule B (RGMB) showed that PD ‐ 1 and CD80 expression correlated with both PD ‐ L1 and PD ‐ L2 in LUAD. CD80 expression correlated with PD ‐ L2 in LUSC. Conclusions: We present gene signatures associated with PD ‐ L1 and PD ‐ L2 mRNA expression in NSCLC which could possess importance in relation to understand PD‐1 checkpoint blockade‐responsive biology and development of gene signature based biomarkers for predicting clinical responses to immunotherapy.

3 April 2017 in Oncogenesis
Verified
Journal Article
Open access
PDF file
KGKristine Raaby Gammelgaard
Kristine Raaby Gammelgaard
CDC Demuth
C Demuth
AMAnne Tranberg Madsen
Anne Tranberg Madsen
DHD Hussmann
D Hussmann
JVJ Vad-Nielsen
J Vad-Nielsen
BSBoe Sorensen
Boe Sorensen
Although many epidermal growth factor receptor (EGFR)-mutated lung cancer patients initially benefit from the EGFR-inhibitor erlotinib, all acquire resistance. So far, several mechanisms implicated in resistance have been identified, but the existence of multiple resistance mechanisms in parallel have only been sparsely investigated. In this study, we investigated parallel resistance mechanisms acquired by HCC827, an EGFR-mutated adenocarcinoma cell line dependent on EGFR activity and sensitive to erlotinib. The cell line was treated with erlotinib by stepwise escalation of the drug-concentration and erlotinib-resistant (HCC827ER) cells created. HCC827ER cells depicted a mixed epithelial and mesenchymal phenotype. To clarify potential parallel resistance mechanisms, 14 resistant subclones were established by limited dilution. Interestingly, all HCC827ER subclones harbored either a MET-amplification (6/14) or underwent EMT (8/14), mechanisms both found in previous studies, but not in co-occurrence. Both subclone-types were resistant to erlotinib, but only MET-subclones responded to the MET-inhibitors crizotinib and capmatinib. EMT-subclones on the other hand had markedly increased FGFR1 expression and responded to the FGFR-inhibitor AZD4547, whereas MET-subclones did not. Monitoring gene expression through the development of HCC827ER revealed upregulation of FGFR1 expression as an early response to erlotinib. In addition, FGFR1 expression increased upon short-term erlotinib treatment (48 h) identifying a physiological role immediately after erlotinib exposure. The high FGFR1 expression seen in EMT-subclones was stable even after five passages without erlotinib. Here we show, that parallel resistance mechanisms appear during erlotinib-resistance development in EGFR-mutated NSCLC cells and highlight a role for FGFR1 expression changes as an early response to erlotinib as well as a bypass-signaling mechanism.

11 January 2016 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
YZYan Zhou
Yan Zhou
YLYong Liu
Yong Liu
DHDianna Hussmann
Dianna Hussmann
PBPeter Brøgger
Peter Brøgger
RARasha Abdelkadhem Al-Saaidi
Rasha Abdelkadhem Al-Saaidi
Yonglun LuoYonglun Luo
Yonglun Luo

10 December 2017
Verified
Book Chapter
Closed access
PDF file
DHDianna Hussmann
Dianna Hussmann
LHLise Lotte Hansen
Lise Lotte Hansen

18 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
DHDianna Hussmann
Dianna Hussmann
AMAnne Tranberg Madsen
Anne Tranberg Madsen
KGKristine Raaby Gammelgaard
Kristine Raaby Gammelgaard
Yonglun LuoYonglun Luo
Yonglun Luo
BSBoe Sorensen
Boe Sorensen
ANAnders Lade Nielsen
Anders Lade Nielsen
IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells